This approach has been explored clinically to address antigen-negative B-ALL relapses, which occur in 10-20% of CD19 CAR T cell recipients, by simultaneously targeting a second antigen like CD20 or CD22 (11, 43). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.